Abstracts Archive - Page 430 of 1683 - ATC Abstracts

2020 American Transplant Congress
Pharmacist Management after Preemptive Monitoring Conversion as a Component of a Cytomegalovirus Antiviral Stewardship Program at a Large Transplant Center
C. Wong, M. Jorgenson, J. Descourouez, K. Goldrosen, C. Saddler, J. Smith, D. Mandelbrot
UW Health, Madison, WI
*Purpose: Cytomegalovirus (CMV) in solid organ transplant (SOT) is associated with negative graft and patient outcomes. Prophylactic agents of choice have substantial cytotoxicity, and patients…
2020 American Transplant Congress
Characteristics of Kidney Transplant Patients Diagnosed with Histoplasmosis
C. Miles, J. Hall, S. Westphal, E. Langewisch
University of Nebraska Medical Center, Omaha, NE
*Purpose: Histoplasmosis is responsible for the greatest number of hospitalizations and deaths due to endemic mycoses in the United States. Although lying near the western…
2020 American Transplant Congress
Donor Derived Parvovirus B19 Infection
W. Peng, J. Lv, J. Wu, J. Chen
Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
*Purpose: At present,donor derived parvovirus B19 infections are rarely reported. Thus, the incidence of donor derived parvovirus B19 infections in solid organ transplant recipients is…
2020 American Transplant Congress
The Incidence, Clinical Characteristics and Prophylactic Strategy of Invasive Fungal Infections in Lung Transplantation
L. Zhao¹, W. Chen¹, L. Guo¹, L. Jing¹, C. Liang¹, J. Chen¹, C. Wang²
¹Department of Lung Transplantation, China-Japan Friendship Hospital, Beijing, China, ²China-Japan Friendship Hospital, Beijing, China
*Purpose: Invasive Fungal infections in lung transplant recipients(LTR) were common and harmful, remaining a major cause of morbidity and mortality after lung transplantation. The incidence,…
2020 American Transplant Congress
The Clinical Impact of HCV D+/r- Kidney Transplantation
S. Meade¹, M. A. Simpson², E. D. Walshe², M. E. Akoad², F. D. Gordon²
¹Lahey Clinic, Burlington, MA, ²Transplantation, Lahey Clinic, Burlington, MA
*Purpose: Transplantation of hepatitis C (HCV) positive organs into HCV negative recipients raises concerns regarding potential for infections unresponsive to DAAs. In September 2018, we…
2020 American Transplant Congress
Access to Direct Acting Antiviral Therapy for Recipients of Solid Organs from Hepatitis C Viremic Donors
C. Edmonds, A. Carver, J. DeClercq, L. Choi, M. Peter, R. Forbes, B. Concepcion, K. Schlendorf, R. Perri
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Emerging data supports transplantation of organs from hepatitis C-positive (HCV) donors to expand the donor pool, but access to direct acting antivirals (DAAs) to…
2020 American Transplant Congress
Incidence of Urinary Tract Infections in Kidney Transplant Recipients Receiving Alternate Antimicrobial Prophylaxis Regimens
D. Quan¹, J. Phillips¹, E. Chiang¹, V. Kuo²
¹UCSF Health, San Francisco, CA, ²UC Davis, Davis, CA
*Purpose: Urinary tract infections (UTI) occur frequently in renal transplant (RT) recipients. Antimicrobial prophylaxis may help prevent UTI early post RT. Trimethoprim/sulfamethoxazole (TMP/SMX) is the…
2020 American Transplant Congress
Transplanting Livers from Hepatitis C Virus Positive Donors; Is it Worth the Risk?
J. W. Mensink¹, B. Van Hoek², B. Schaefer³, M. D. Van Rosmalen⁴, I. P. Alwayn⁵, A. E. Braat⁵
¹Leiden University Medical Center, Leiden, Netherlands, ²Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, Netherlands, ³Dutch Transplant Foundation, Leiden, Netherlands, ⁴Eurotransplant International Foundation, Leiden, Netherlands, ⁵Transplant Surgery, Leiden University Medical Center, Leiden, Netherlands
*Purpose: Before the introduction of Direct-Acting Antivirals (DAAs), only selected organs from Hepatitis C virus (HCV) positive donors were successfully transplanted into HCV positive recipients.…
2020 American Transplant Congress
Use of Direct Acting Antiviral Medications in Transplant Recipients Receiving Organs from Hepatitis C Viremic Donors
S. Bova¹, A. Cameron¹, C. Durand¹, J. Katzianer², M. LeGrand², L. Boyer¹, J. Glorioso³, L. P. Toman¹
¹The Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins Home Care Group, Baltimore, MD, ³Thomas Jefferson Univeristy Hospital, Philadelphia, PA
*Purpose: The availability and high efficacy of direct acting antivirals (DAAs) to treat hepatitis C (HCV) is changing practice in solid organ transplant. A large…
2020 American Transplant Congress
Using HCV Infected Organs and the Challenge of Third-Party Payers
R. Daloul, A. Michaels, L. Sobotka, T. Pesavento, K. Washburn
Comprhensive Transplant Center, The Ohio State University, Columbus, OH
*Purpose: The practice of transplanting organs from hepatitis C viremic donors (HCV NAT+) into negative recipients hinges on the ability to ensure direct acting antiviral…